CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported new results from Study 9001-103. Also known as ...
Expanded safety, subgroup, progression-free survival sensitivity and subsequent therapy analyses further characterize the consistency and durability of outcomes observed with zanidatamab-containing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results